top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
Antidepressant use among adults : United States, 2015-2018 / / Debra J. Brody, and Qiuping Gu
Antidepressant use among adults : United States, 2015-2018 / / Debra J. Brody, and Qiuping Gu
Autore Brody Debra J.
Pubbl/distr/stampa Hyattsville, MD : , : U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, , 2020
Descrizione fisica 1 online resource (7 pages, 1 unnumbered page) : color illustrations
Collana NCHS data brief
Soggetto topico Depression, Mental - Treatment
Antidepressants - United States
Antidepressants
Psychotropic drugs
Soggetto genere / forma Statistics.
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Altri titoli varianti Antidepressant use among adults
Record Nr. UNINA-9910715343803321
Brody Debra J.  
Hyattsville, MD : , : U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, , 2020
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
The approved mental health professional's guide to psychiatry and medication [[electronic resource] /] / Robert Brown, Gwen Adshead, Alan Pollard
The approved mental health professional's guide to psychiatry and medication [[electronic resource] /] / Robert Brown, Gwen Adshead, Alan Pollard
Autore Brown Robert <1949->
Edizione [2nd ed.]
Pubbl/distr/stampa Exeter [England], : Learning Matters, 2009
Descrizione fisica 1 online resource (145 p.)
Disciplina 362.2
616.8918
Altri autori (Persone) AdsheadGwen
PollardAlan
Collana Post-qualifying social work practice
Soggetto topico Psychiatric social work - Great Britain
Mental illness - Treatment
Psychotropic drugs
Soggetto genere / forma Electronic books.
ISBN 1-84445-553-X
1-282-48464-8
9786612484643
1-84445-830-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover; Prelims; Chapter 1 The importance of psychiatry and medication for Approved Mental Health Professionals; Chapter 2 Psychiatrists: training and how they practise; Chapter 3 An overview of psychiatry and classification; Chapter 4 Psychotic disorders; Chapter 5 Neurotic disorders, substance abuse and personality disorders; Chapter 6 Forensic psychiatry; Chapter 7 Psychiatry of old age; Chapter 8 Psychiatry and risk assessment; Chapter 9 Patients as parents; Chapter 10 Child and adolescent psychiatry; Chapter 11 Treatment issues in psychiatry
Chapter 12 Classification of medication in psychiatryChapter 13 Anti-depressants and mood stabilisers; Chapter 14 Anti-psychotics (BNF section 4.2); Chapter 15 Anxiolytics and sedative/ hypnotics (BNF section 4.1); Chapter 16 Older adults, children, unlicensed drugs; Chapter 17 The law and psychiatric treatment; Chapter 18 Treatment under the Mental Health Act; Statutes; Some useful websites; References; Index
Record Nr. UNINA-9910456487803321
Brown Robert <1949->  
Exeter [England], : Learning Matters, 2009
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
The approved mental health professional's guide to psychiatry and medication [[electronic resource] /] / Robert Brown, Gwen Adshead, Alan Pollard
The approved mental health professional's guide to psychiatry and medication [[electronic resource] /] / Robert Brown, Gwen Adshead, Alan Pollard
Autore Brown Robert <1949->
Edizione [2nd ed.]
Pubbl/distr/stampa Exeter [England], : Learning Matters, 2009
Descrizione fisica 1 online resource (145 p.)
Disciplina 362.2
616.8918
Altri autori (Persone) AdsheadGwen
PollardAlan
Collana Post-qualifying social work practice
Soggetto topico Psychiatric social work - Great Britain
Mental illness - Treatment
Psychotropic drugs
ISBN 1-84445-553-X
1-282-48464-8
9786612484643
1-84445-830-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover; Prelims; Chapter 1 The importance of psychiatry and medication for Approved Mental Health Professionals; Chapter 2 Psychiatrists: training and how they practise; Chapter 3 An overview of psychiatry and classification; Chapter 4 Psychotic disorders; Chapter 5 Neurotic disorders, substance abuse and personality disorders; Chapter 6 Forensic psychiatry; Chapter 7 Psychiatry of old age; Chapter 8 Psychiatry and risk assessment; Chapter 9 Patients as parents; Chapter 10 Child and adolescent psychiatry; Chapter 11 Treatment issues in psychiatry
Chapter 12 Classification of medication in psychiatryChapter 13 Anti-depressants and mood stabilisers; Chapter 14 Anti-psychotics (BNF section 4.2); Chapter 15 Anxiolytics and sedative/ hypnotics (BNF section 4.1); Chapter 16 Older adults, children, unlicensed drugs; Chapter 17 The law and psychiatric treatment; Chapter 18 Treatment under the Mental Health Act; Statutes; Some useful websites; References; Index
Record Nr. UNINA-9910780819003321
Brown Robert <1949->  
Exeter [England], : Learning Matters, 2009
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
The approved mental health professional's guide to psychiatry and medication / / Robert Brown, Gwen Adshead, Alan Pollard
The approved mental health professional's guide to psychiatry and medication / / Robert Brown, Gwen Adshead, Alan Pollard
Autore Brown Robert <1949->
Edizione [2nd ed.]
Pubbl/distr/stampa Exeter [England], : Learning Matters, 2009
Descrizione fisica 1 online resource (145 p.)
Disciplina 362.2
616.8918
Altri autori (Persone) AdsheadGwen
PollardAlan
Collana Post-qualifying social work practice
Soggetto topico Psychiatric social work - Great Britain
Mental illness - Treatment
Psychotropic drugs
ISBN 1-84445-553-X
1-282-48464-8
9786612484643
1-84445-830-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover; Prelims; Chapter 1 The importance of psychiatry and medication for Approved Mental Health Professionals; Chapter 2 Psychiatrists: training and how they practise; Chapter 3 An overview of psychiatry and classification; Chapter 4 Psychotic disorders; Chapter 5 Neurotic disorders, substance abuse and personality disorders; Chapter 6 Forensic psychiatry; Chapter 7 Psychiatry of old age; Chapter 8 Psychiatry and risk assessment; Chapter 9 Patients as parents; Chapter 10 Child and adolescent psychiatry; Chapter 11 Treatment issues in psychiatry
Chapter 12 Classification of medication in psychiatryChapter 13 Anti-depressants and mood stabilisers; Chapter 14 Anti-psychotics (BNF section 4.2); Chapter 15 Anxiolytics and sedative/ hypnotics (BNF section 4.1); Chapter 16 Older adults, children, unlicensed drugs; Chapter 17 The law and psychiatric treatment; Chapter 18 Treatment under the Mental Health Act; Statutes; Some useful websites; References; Index
Record Nr. UNINA-9911098289903321
Brown Robert <1949->  
Exeter [England], : Learning Matters, 2009
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
The approved mental health professional's guide to psychiatry and medication / / Robert Brown, Gwen Adshead, Alan Pollard
The approved mental health professional's guide to psychiatry and medication / / Robert Brown, Gwen Adshead, Alan Pollard
Autore Brown Robert <1949->
Edizione [2nd ed.]
Pubbl/distr/stampa Exeter [England], : Learning Matters, 2009
Descrizione fisica 1 online resource (145 p.)
Disciplina 362.2
616.8918
Altri autori (Persone) AdsheadGwen
PollardAlan
Collana Post-qualifying social work practice
Soggetto topico Psychiatric social work - Great Britain
Mental illness - Treatment
Psychotropic drugs
ISBN 1-84445-553-X
1-282-48464-8
9786612484643
1-84445-830-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover; Prelims; Chapter 1 The importance of psychiatry and medication for Approved Mental Health Professionals; Chapter 2 Psychiatrists: training and how they practise; Chapter 3 An overview of psychiatry and classification; Chapter 4 Psychotic disorders; Chapter 5 Neurotic disorders, substance abuse and personality disorders; Chapter 6 Forensic psychiatry; Chapter 7 Psychiatry of old age; Chapter 8 Psychiatry and risk assessment; Chapter 9 Patients as parents; Chapter 10 Child and adolescent psychiatry; Chapter 11 Treatment issues in psychiatry
Chapter 12 Classification of medication in psychiatryChapter 13 Anti-depressants and mood stabilisers; Chapter 14 Anti-psychotics (BNF section 4.2); Chapter 15 Anxiolytics and sedative/ hypnotics (BNF section 4.1); Chapter 16 Older adults, children, unlicensed drugs; Chapter 17 The law and psychiatric treatment; Chapter 18 Treatment under the Mental Health Act; Statutes; Some useful websites; References; Index
Record Nr. UNINA-9911151511303321
Brown Robert <1949->
Exeter [England], : Learning Matters, 2009
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Aspects of psychopharmacology / / edited by D.J. Sanger and D.E. Blackman
Aspects of psychopharmacology / / edited by D.J. Sanger and D.E. Blackman
Pubbl/distr/stampa Abingdon, Oxon : , : Routledge, , 2017
Descrizione fisica 1 online resource (240 pages) : illustrations, graphs
Disciplina 615.78
Altri autori (Persone) Blackmanderek E
SangerD. J
Collana Routledge Library Editions: Addictions
Soggetto topico Psychopharmacology
Psychotropic drugs
Substance abuse
ISBN 1-315-53605-6
1-315-53604-8
9781315536057
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto 1. Introduction to psychopharmacology and basic neuropharmacology / A.J. Greenshaw, D.J. Sanger and D.E. Blackman -- 2. Behavioural principles in psychopharmacology / James E. Barrett -- 3. Internal stimulus effects of drugs / I.P. Stolerman -- 4. Alcohol and alcoholism / Geoff Lowe -- 5. Social aspects of illegal drug use / Raymond Cochrane -- 6. Drugs and human memory / C.M. Smith -- 7. The use of drugs in psychiatry / P.E. Harrison-Read -- 8. Contemporary psychopharmacology : a review / D.J. Sanger and D.E. Blackman.
Record Nr. UNINA-9910136150103321
Abingdon, Oxon : , : Routledge, , 2017
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Clinical manual of psychopharmacology in the medically ill / / edited by James L. Levenson, M.D., Stephen J. Ferrando, M.D
Clinical manual of psychopharmacology in the medically ill / / edited by James L. Levenson, M.D., Stephen J. Ferrando, M.D
Edizione [Second edition.]
Pubbl/distr/stampa Arlington, Virginia : , : American Psychiatric Association Publishing, , [2017]
Descrizione fisica 1 online resource (xxv, 838 pages) : illustrations
Disciplina 615.78
Soggetto topico Psychotropic drugs
Soggetto genere / forma Electronic books.
ISBN 1-61537-107-9
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910494650103321
Arlington, Virginia : , : American Psychiatric Association Publishing, , [2017]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Clinical trials in psychopharmacology : a better brain / / editors, Marc Hertzman, Lawrence Adler
Clinical trials in psychopharmacology : a better brain / / editors, Marc Hertzman, Lawrence Adler
Autore Hertzman Marc
Edizione [2nd ed.]
Pubbl/distr/stampa Wiley, 2010
Descrizione fisica 1 online resource (422 p.)
Disciplina 615/.78
Altri autori (Persone) HertzmanMarc
AdlerLawrence
Soggetto topico Psychopharmacology
Psychotropic drugs
Clinical trials
ISBN 9786612548161
9781282548169
1282548166
9780470749180
0470749180
9780470749173
0470749172
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Clinical Trials in Psychopharmacology; Contents; Acknowledgments; Introduction; List of Contributors; SECTION I: The Health Care Environment and Medications; 1. FDA Reform: D ́ej`a vu Encore; 1.1 Introduction; 1.2 The 1992 prescription drug user fee act adds funds and changes FDA's focus; 1.3 PDUFA shortens drug review times and eliminates the drug lag; 1.4 PDUFA timetables feed safety concerns; 1.5 FDA responds to safety concerns; 1.6 The pipeline problem; 1.7 The 2007 FDA Science Board's Subcommittee on Science and Technology report
1.8 The FDAAA of 2007 reauthorize PDUFA and provide new authority to address safety and the critical path initiative1.9 The impact of PDFUA on FDA; 1.10 Comparative medical benefits, comparative effectiveness and FDA; 1.11 FDA and non-inferiority trials; 1.12 FDA and CMS decisions on Medicare coverage; 1.13 Preemption: FDA's role in relation to liability litigation in state courts; 1.14 FDA's exclusivity in allowing access to experimental drugs; 1.15 Conclusions; 2. Do Antidepressants Cause Suicide?; 2.1 Some definitional problems
2.2 A brief history of the concerns of suicidality caused by antidepressants2.3 Politics rears its ugly head; 2.4 The FDA responds; 2.5 What changes in public policy wrought; 2.6 A funny thing happened on the way to the forum; 2.7 Meanwhile back at the ranch; 2.8 Moral (maybe); 3. The Genome, Genes and Brain - Tailored Drugs; 3.1 Introduction; 3.2 Issues in new drug development; 3.3 Early development of psychiatric pharmaceutical entities; 3.4 Advances in research technology; 3.5 Review of genetics; 3.6 Activation of genes by signal transduction cascades; 3.7 The human genome
3.8 The sequencing of the genome3.9 DNA variation; 3.10 Genes and illness; 3.11 Genomic findings, potential targets and new drug development; 3.12 Conclusion; 4. Patenting and Licensing Concerns in Psychiatric Genetics; 4.1 Genetic diagnoses in psychiatry; 4.2 The evolving patent landscape in psychiatry; 4.3 Approaches to solving potential problems; 4.4 Conclusions; 5. Women's Issues in Clinical Trials; 5.1 History; 5.2 Perceived advantages of excluding women; 5.3 Change in perspective; 5.4 Have things changed?; 5.5 Progress since 1993; 5.6 Reported current difficulties in including women
5.7 Contraception in clinical trials5.8 Drugs in lactating women; 5.9 How often do women take drugs during pregnancy?; 5.10 Ethical issues: risk/benefit analysis; 5.11 Adequate information; 5.12 Adolescent women; 5.13 Recruitment and retention of women; SECTION II: Clinical Trials and Mood Disorders; 6. Issues and Clues in the Pharmacological Treatment of Mood Disorders; 6.1 What do we know about mood disorders that may be relevant for their pharmacological treatment?; 6.2 Are there clues for the pharmacological treatment of mood disorders?; 6.3 Perspectives; 7. Bipolar Disorder
7.1 Introduction
Record Nr. UNINA-9910813016803321
Hertzman Marc  
Wiley, 2010
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Clinical trials in psychopharmacology [[electronic resource] ] : a better brain / / editors, Marc Hertzman, Lawrence Adler
Clinical trials in psychopharmacology [[electronic resource] ] : a better brain / / editors, Marc Hertzman, Lawrence Adler
Edizione [2nd ed.]
Pubbl/distr/stampa Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2010
Descrizione fisica 1 online resource (422 p.)
Disciplina 615/.78
Altri autori (Persone) HertzmanMarc
AdlerLawrence
Soggetto topico Psychopharmacology
Psychotropic drugs
Clinical trials
ISBN 1-282-54816-6
9786612548161
0-470-74918-0
0-470-74917-2
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Clinical Trials in Psychopharmacology; Contents; Acknowledgments; Introduction; List of Contributors; SECTION I: The Health Care Environment and Medications; 1. FDA Reform: D ́ej`a vu Encore; 1.1 Introduction; 1.2 The 1992 prescription drug user fee act adds funds and changes FDA's focus; 1.3 PDUFA shortens drug review times and eliminates the drug lag; 1.4 PDUFA timetables feed safety concerns; 1.5 FDA responds to safety concerns; 1.6 The pipeline problem; 1.7 The 2007 FDA Science Board's Subcommittee on Science and Technology report
1.8 The FDAAA of 2007 reauthorize PDUFA and provide new authority to address safety and the critical path initiative1.9 The impact of PDFUA on FDA; 1.10 Comparative medical benefits, comparative effectiveness and FDA; 1.11 FDA and non-inferiority trials; 1.12 FDA and CMS decisions on Medicare coverage; 1.13 Preemption: FDA's role in relation to liability litigation in state courts; 1.14 FDA's exclusivity in allowing access to experimental drugs; 1.15 Conclusions; 2. Do Antidepressants Cause Suicide?; 2.1 Some definitional problems
2.2 A brief history of the concerns of suicidality caused by antidepressants2.3 Politics rears its ugly head; 2.4 The FDA responds; 2.5 What changes in public policy wrought; 2.6 A funny thing happened on the way to the forum; 2.7 Meanwhile back at the ranch; 2.8 Moral (maybe); 3. The Genome, Genes and Brain - Tailored Drugs; 3.1 Introduction; 3.2 Issues in new drug development; 3.3 Early development of psychiatric pharmaceutical entities; 3.4 Advances in research technology; 3.5 Review of genetics; 3.6 Activation of genes by signal transduction cascades; 3.7 The human genome
3.8 The sequencing of the genome3.9 DNA variation; 3.10 Genes and illness; 3.11 Genomic findings, potential targets and new drug development; 3.12 Conclusion; 4. Patenting and Licensing Concerns in Psychiatric Genetics; 4.1 Genetic diagnoses in psychiatry; 4.2 The evolving patent landscape in psychiatry; 4.3 Approaches to solving potential problems; 4.4 Conclusions; 5. Women's Issues in Clinical Trials; 5.1 History; 5.2 Perceived advantages of excluding women; 5.3 Change in perspective; 5.4 Have things changed?; 5.5 Progress since 1993; 5.6 Reported current difficulties in including women
5.7 Contraception in clinical trials5.8 Drugs in lactating women; 5.9 How often do women take drugs during pregnancy?; 5.10 Ethical issues: risk/benefit analysis; 5.11 Adequate information; 5.12 Adolescent women; 5.13 Recruitment and retention of women; SECTION II: Clinical Trials and Mood Disorders; 6. Issues and Clues in the Pharmacological Treatment of Mood Disorders; 6.1 What do we know about mood disorders that may be relevant for their pharmacological treatment?; 6.2 Are there clues for the pharmacological treatment of mood disorders?; 6.3 Perspectives; 7. Bipolar Disorder
7.1 Introduction
Record Nr. UNINA-9910139427703321
Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2010
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Comite de Expertos de la OMS en Farmacodependencia : 34o informe
Comite de Expertos de la OMS en Farmacodependencia : 34o informe
Edizione [1st ed.]
Pubbl/distr/stampa Ginebra, : Organizacion Mundial de la Salud, 2007
Descrizione fisica 1 online resource (36 p.)
Disciplina 363.29
Collana OMS, Serie de informes tecnicos
Soggetto topico Psychotropic drugs
Psychotropic drugs - Physiological effect
Psychopharmacology
Drug control
Health services administration
ISBN 1-281-30761-0
9786611307615
92-4-068259-7
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione spa
Record Nr. UNINA-9911101158603321
Ginebra, : Organizacion Mundial de la Salud, 2007
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui